Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
The treatment landscape for gliomas has evolved rapidly in recent years, following an enhanced understanding of the molecular underpinnings, which has driven the development of novel approaches aimed at personalizing care. The recent approvals of new targeted therapies for molecular subsets, including IDH1/2, BRAF, and H3 K27M mutations, represent important progress driven by advances in molecular diagnostics and targeted therapies. Additionally, novel immunotherapeutic approaches continue to be investigated in gliomas, specifically high-grade gliomas. However, the complex biology of gliomas and the rapid pace of therapeutic development are creating knowledge and competence gaps among clinicians managing these conditions. Thus, there is a need for educational programs that discuss recent advances as well as emerging approaches in glioma management to help clinicians develop strategies to integrate recently approved novel therapies in clinical practice to optimize outcomes for patients with these tumors.
This Medical Crossfire® program provides up-to-date clinical trial data and ongoing studies in gliomas. The Medical Crossfire® approach offers an ideal format for participants, allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and obtain expert opinions on optimally integrating the latest therapies into treatment paradigms for patients with gliomas.
This educational activity is an archive of the live virtual symposium held on November 21, 2025.
Target Audience
This educational activity is directed toward medical oncologists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers involved in the treatment and management of gliomas.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate genetic and molecular information along with recent classification criteria to accurately diagnose, classify, and develop personalized care plans for patients with glioma
- Determine the implications of recent developments in targeted and immunotherapeutic strategies on individualizing treatment for patients with glioma
- Assess the impact of current and emerging targeted and immunotherapy strategies on personalizing care for pediatric patients with glioma.
Vinay K. Puduvalli, MD
Professor and Chair, Department of Neuro-Oncology
Co-Director, Cancer Neuroscience Program
Co-Director, NeuroHealth Initiative
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory Board: Boehringer Ingelheim, Guidepoint, Novocure, Orbus Therapeutics, Servier, Tango Therapeutics, Telix Pharmaceuticals; Honorarium: Boehringer Ingelheim, Guidepoint, Novocure, Orbus Therapeutics, Servier, Tango Therapeutics, Telix Pharmaceuticals
Manmeet Ahluwalia, MD, MBA, FASCO
Professor of Translational Medicine
Herbert Wertheim College of Medicine, Florida International University
Fernandez Family Foundation Endowed Chair in Cancer Research
Chief of Medical Oncology, Chief Scientific Officer, and Deputy Director
Baptist Health Miami Cancer Institute
Miami, FL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AlloVir, Apollomics, Autem Therapeutics, Bayer, Bugworks, Equillium, GT Medical Technologies, Incyte, Modifi Biosciences, Novocure, Recordati, Servier Pharmaceuticals, VBI Vaccines, Xoft; Grant/ Research Funding: Incyte, Pfizer; Ownership Interests: Live AI, Mimivax, Ryght AI, Trisalus Life Sciences
Girish Dhall, MD
Professor and Head, UAB Division of Pediatric Hematology, Oncology, and Blood & Marrow Transplantation
Benjamin Russell Endowed Chair in Pediatric Hematology/Oncology
Heersink School of Medicine
The University of Alabama at Birmingham
Birmingham, AL
Disclosures: Girish Dhall, MD, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.